immunotherapy for sclc and the "four ps" in managed care—patient, provider, pharmacy, and plan
Published 3 years ago • 284 plays • Length 1:31:04Download video MP4
Download video MP3
Similar videos
-
51:59
facilitating progress in the treatment of sclc
-
1:08:56
toward better outcomes in sclc: immunotherapy has changed the game, but where do we go next?
-
1:03:14
changing the game for es-sclc with immunotherapy and multidisciplinary collaboration
-
5:15
chemoimmunotherapy in sclc - 2022 program: lcvl
-
1:24:26
assessing the impact of therapeutic advances in sclc
-
1:08:52
integrating new options into the sclc treatment arsenal to improve patient outcomes
-
59:24
marking new milestones with immunotherapy in locally advanced and early lung cancer
-
0:58
combining immunotherapy and chemotherapy in patients with sclc
-
1:04:50
a new era has begun in the treatment of sclc: navigating novel therapeutic options and strategies
-
1:27:09
optimal sclc care with established and innovative therapies
-
15:57
2021 west oncology | lung cancer | updates on immunotherapy and small cell lung cancer stage 4
-
0:48
adriatic study: new standard of care treatment for small cell lung cancer
-
2:54
best results ever in the treatment of small cell lung cancer: immunotherapy in primary care
-
1:10:25
how to select the right immunotherapy for first-line treatment of advanced nsclc
-
3:00
small-cell lung cancer: future directions in care
-
0:53
any role of chemotherapy in high pdl1 metastatic non-small cell lung cancer in 1l?
-
0:12
why immunotherapy should be standard in cancer care
-
0:45
dr. jacob sands on the advances in treatment of small cell lung cancer #sclc #lungcancer
-
52:29
improving outcomes in resectable nsclc: decisions about neoadjuvant and adjuvant immunotherapy